Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
You probably missed the context, but its fine | Investor2014 | investorshub | 07/17/2024 6:42:58 PM |
Is that you buying? | WolfofMia | investorshub | 07/17/2024 6:33:28 PM |
It's growing well. | AstroVolcano10 | investorshub | 07/17/2024 5:54:04 PM |
Thank you. Dooly noted. | ignatiusrielly35 | investorshub | 07/17/2024 5:45:33 PM |
$AVXL finally turned green: 5.85 +0.02 | RedShoulder | investorshub | 07/17/2024 5:42:03 PM |
Re; Eggzactly | meds4life | investorshub | 07/17/2024 5:31:59 PM |
In anticipation of GREAT NEWS NEXT WEEK and | georgejjl | investorshub | 07/17/2024 4:58:50 PM |
Awww but thank you!! | WolfofMia | investorshub | 07/17/2024 4:55:42 PM |
Where is AD RNA data and new rettt | kund | investorshub | 07/17/2024 4:51:27 PM |
Maria is passionate and she has put her | kund | investorshub | 07/17/2024 4:47:20 PM |
Lunch finds me stopped out earlier. | LakeshoreLeo1953 | investorshub | 07/17/2024 4:31:01 PM |
There is a lot of competition, but still | Investor2014 | investorshub | 07/17/2024 4:23:36 PM |
True, but doesn't always hurt. | kevindenver | investorshub | 07/17/2024 4:20:39 PM |
I still believe in the CEO at $ANVS....seems | kevindenver | investorshub | 07/17/2024 4:17:06 PM |
Yea you are right my ignorant friend wonders | WolfofMia | investorshub | 07/17/2024 4:16:20 PM |
Landing closer to $4.6.. | KIPK | investorshub | 07/17/2024 4:13:23 PM |
SAVA has had a lot of shares traded | georgejjl | investorshub | 07/17/2024 4:11:27 PM |
What shares? I thought no one believes I | Investor2014 | investorshub | 07/17/2024 4:06:07 PM |
So did you sell your share yet? | WolfofMia | investorshub | 07/17/2024 3:51:08 PM |
You are absolutely correct about the following: | georgejjl | investorshub | 07/17/2024 3:43:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...